Scott N Boyle C4 Therapeutics, Inc. (CCCC) insider trading activity

Scott N Boyle is Chief Business Officer of C4 Therapeutics, Inc.. Currently has a direct ownership of 107,805 shares of CCCC, which is worth approximately $292,151. The most recent transaction as insider was on Feb 18, 2025, when has been sold 669 shares (Common Stock) at a price of $3.15 per share, resulting in proceeds of $2,107. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 108K

90.58% 3M change

106.01% 12M change

Total Value Held $292,151

Scott N Boyle Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 18 2025	SELL Open market or private sale	$2,107 $3.15 p/Share	669 Reduced 0.62%	107,805 Common Stock
Feb 14 2025	SELL Open market or private sale	$1,543 $3.15 p/Share	490 Reduced 0.44%	110,842 Common Stock
Feb 14 2025	SELL Payment of exercise price or tax liability	$7,530 $3.18 p/Share	2,368 Reduced 2.14%	108,474 Common Stock
Feb 14 2025	BUY Grant, award, or other acquisition	-	56,500 Added 33.66%	111,332 Common Stock
Feb 13 2025	SELL Payment of exercise price or tax liability	$5,552 $3.2 p/Share	1,735 Reduced 3.07%	54,832 Common Stock
Nov 07 2024	SELL Payment of exercise price or tax liability	$6,656 $6.04 p/Share	1,102 Reduced 1.91%	56,567 Common Stock
Nov 07 2024	BUY Exercise of conversion of derivative security	-	3,750 Added 6.11%	57,669 Common Stock
Sep 16 2024	SELL Payment of exercise price or tax liability	$4,203 $6.36 p/Share	661 Reduced 1.21%	53,919 Common Stock
Sep 16 2024	BUY Exercise of conversion of derivative security	-	2,250 Added 3.96%	54,580 Common Stock
Feb 14 2024	BUY Grant, award, or other acquisition	-	27,300 Added 34.28%	52,330 Common Stock
Feb 13 2024	SELL Payment of exercise price or tax liability	$11,329 $6.53 p/Share	1,735 Reduced 6.48%	25,030 Common Stock
Aug 30 2023	SELL Payment of exercise price or tax liability	$1,936 $2.93 p/Share	661 Reduced 2.41%	26,765 Common Stock
Aug 30 2023	BUY Exercise of conversion of derivative security	-	2,250 Added 7.58%	27,426 Common Stock
Feb 13 2023	BUY Grant, award, or other acquisition	-	20,000 Added 44.27%	25,176 Common Stock
Jan 30 2023	SELL Payment of exercise price or tax liability	$9,507 $7.78 p/Share	1,222 Reduced 19.1%	5,176 Common Stock
Jan 30 2023	BUY Exercise of conversion of derivative security	-	3,750 Added 36.95%	6,398 Common Stock
May 25 2022	BUY Exercise of conversion of derivative security	-	3,750 Added 50.0%	3,750 Common Stock

SNB

Scott N Boyle

Chief Business Officer

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CCCC shares.

Notify only if

Value

Insider Trading

Get notified when an C4 Therapeutics, Inc. insider buys or sells CCCC shares.

Notify only if

Operation

Value

Type

News

Receive news related to C4 Therapeutics, Inc.

Track Activities on CCCC

Account